Tumor treating fields: narrative review of a promising treatment modality for cancer

Chin Clin Oncol. 2023 Dec;12(6):64. doi: 10.21037/cco-23-82. Epub 2023 Nov 2.

Abstract

Background and objective: Tumor treating fields (TTFields) therapy have emerged as a potentially effective treatment for various malignancies by delivering low-intensity, intermediate-frequency electrical fields that disrupt many processes inside cells, resulting in the interruption of cell division in cancer cells. Additionally, TTFields therapy has been found to be synergistic with existing therapeutic approaches. In this review, we provide an introduction and background to the primary mechanisms of TTFields and discuss the emerging preclinical and clinical outcomes of this novel cancer treatment technology.

Methods: We performed a literature search on PubMed, ClinicalTrials.Gov, and Google Scholar using the terms 'TTFields' and 'cancer'. We included studies, review articles, and editorials published in English from 1st January 2000 to 1st October 2023. All obtained publications were reviewed and their key references are cross-checked to ensure a balanced and high-quality review.

Key content and findings: Clinical studies reported to date have demonstrated the survival advantage of TTFields therapy in newly diagnosed glioblastoma (GBM), non-small cell lung cancer (NSCLC), and meaningful clinical activity in recurrent GBM (rGBM) and malignant pleural mesothelioma. Moreover, TTFields therapy has exhibited promising safety profiles across a diverse range of cancers including pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, NSCLC, and gastric cancer, when combined with cytotoxic chemotherapy and/or immunotherapy regimens, suggesting broad applicability as an added treatment modality.

Conclusions: Based on preclinical and clinical studies, TTFields therapy show promise as a potential treatment option for patients with a number of different malignancies, offering a favorable safety profile and the potential for significant clinical benefit. Further research is warranted to establish the optimal treatment parameters and identify specific patient subgroups that may derive the greatest advantage from this treatment modality.

Keywords: Tumor treating fields (TTFields); cancer; electric fields.

Publication types

  • Review

MeSH terms

  • Brain Neoplasms* / therapy
  • Carcinoma, Hepatocellular*
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Combined Modality Therapy
  • Glioblastoma* / therapy
  • Humans
  • Liver Neoplasms*
  • Lung Neoplasms* / pathology
  • Neoplasm Recurrence, Local